Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
21 November 2024
| Name: | TBG DIAGNOSTICS LIMITED (TDL) | |||||||||
| ISIN: | AU000000TDL4 | |||||||||
| Date of Listing: | 22 December 1995 | |||||||||
| Date of Delisting: | 30 August 2021 | |||||||||
| Former Names: |
|
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 30 August 2021.Legal Status:
ACN: 010 975 612ABN: 82 010 975 612
Registration Date: 26 September 1989
Capital Gains Tax (CGT) Status:
The securities in this entity, in our opinion, are of little or no value. We have made that assessment by reference to the circumstances leading to a suspension and/or delisting, the length of a suspension, share trading history and last on-market share price, most recent financial and cash flow statements, prospects (including likelihood of re-financing), and other factors including in particular whether the entity is in external administration. If you are seeking to crystallise a capital loss on your securities, that process can be easily and quickly initiated at our online Worthless Shares facility here: https://www.delisted.com.au/sell-worthless-and-other-securities/.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| TBG DIAGNOSTICS LIMITED | 02/02/2016 | |
| PROGEN PHARMACEUTICALS LIMITED | 02/04/2007 | 02/02/2016 |
| PROGEN INDUSTRIES LIMITED | 02/04/2007 |
REGISTRY:
Computershare Brisbane
Level 1, 200 Mary Street Brisbane QLD 4000
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 7 3229 9860
RegistryWebsite RegistryEmail
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 10/07/2024 |
delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15 | 30/08/2021 |
we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2022 | 30/08/2021 |
The company has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2022, and the entity's securities are already suspended from quotation. | 23/08/2021 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 03/08/2021 |
The company releases the results of its meeting. | 29/07/2021 |
The company releases a Restatement of its FY2020 Financial Statements. | 29/07/2021 |
The company releases its Annual General Meeting Letter to Shareholders. | 25/06/2021 |
The company's 2020 AGM will be held at 1:00 pm (AEST) 29 July 2021 via a virtual meeting. | 25/06/2021 |
TBG Diagnostics Limited has entered into an agreement for the sale of shares held by the Company in its subsidiary company, TBG Inc. with Dong Yuan Hua Xin (Beijing) Capital Management Limited Company. The Company is selling approximately 5% of TBG Inc to Dong Yuan under this transaction. Following completion of the Company's sale of 5% of TBG Inc to Dong Yuan pursuant to the Agreement, the Company will hold a 41.25% shareholding and Dong Yuan will hold a 38.71% shareholding in TBG Inc. | 07/06/2021 |
The company will hold its AGM on 29 July 2021. The time and other details relating to the meeting will be advised in the notice of meeting to be sent in due course. The period for nomination of directors will close on 10 June 2021. | 20/05/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 03/05/2021 |
The company releases an Appendix 4G. | 31/03/2021 |
The company lodges its Annual Report to shareholders. | 31/03/2021 |
The company lodges its Full Year Statutory Accounts. | 31/03/2021 |
On 12 March 2021, ASIC made a determination restricting TBG Diagnostics Limited from relying on the exceptions in sectin 713 to use transactino-specific disclosure until 11 March 2022. This restriction means that the company will not be able to rely on the reduced disclosure rules under section 713 and instead must issue a full prospectus in order to raise funds from certain investors. The restriction will not affect the operation and business of TDL. | 18/03/2021 |
The company issues a Response to ASX Query Letter. | 03/03/2021 |
The company lodges its Preliminary Final Report. | 26/02/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 01/02/2021 |
The company releases its Securities Trading Policy. | 20/11/2020 |
The company's investee company, TBG Biotechnology XIamen, has received the CE Mark approval for its SARS-CoV-2 Antigen Rapid Test. | 11/11/2020 |
The company lodges its Quarterly Activities Report. | 02/11/2020 |
The company lodges its Appendix 4C - quarterly. | 02/11/2020 |
The company's wholly owned subsisiary, TBG Biotechnology Corp., entered into a distribution agreement with Medigen Biotechnology Corp. on 15 February 2020 to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit and Nucleic Acid Test Kit. The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen. | 21/09/2020 |
The company's wholly owned subsidiary, TBG Biotechnology Corp., has received an Emergency Use Authorisation from the U.S. FDA for its TBG SARS-CoV-2 IgG / IgM Rapid Test Kit. | 02/09/2020 |
The company lodges its Half Yearly Report and Accounts. | 31/08/2020 |
The company lodges its Quarterly Activities Report. | 31/07/2020 |
The company lodges its Appendix 4C - quarterly. | 31/07/2020 |
The company releases the Results of its Meeting. | 31/07/2020 |
TBG Diagnostics Limited's wholly owned subsidiary, TBG Biotechnology Corp., has received an emergency use authorisation from the Taiwan Ministry of Health and Welfare for its ExProbe SARS-CoV-2 Testing Kit. | 29/07/2020 |
The company's 2019 AGM will be held at 12:30 pm (AEST) 31 July 2020 at Boardroom, Level 27 101 Collins Street Melbourne VIC. | 26/06/2020 |
The company releases an Appendix 4G. | 15/06/2020 |
The company lodges its Annual Report to shareholders. | 15/06/2020 |
The company lodges its Full Year Statutory Accounts. | 12/06/2020 |
TBG Biotechnology Corp. has received an Emergency Use Authorisation from the United States Food and Drug Administration for its ExProbe SARS-CoV-2 Testing Kit. | 12/06/2020 |
The company will hold its AGM on 31 July 2020. The time and other details relating to the meeting will be advised in the Notice of Meeting to be sent in due course. The period for nomination of Directors will close on 18 June 2020. | 11/06/2020 |
The company's wholly owned subsidiary, TBG Biotechnology Corp., has received the CE Mark approval for its ExProbe SARS-CoV-2 Testing Kit and SARS-CoV-2 IgG / IgM Rapid Test Kit. | 21/05/2020 |
The company has received notification from TBG Biotechnology Xiamen Inc. that the Chinese Department of Commerce has lifted the bans restricting the exportation of TBG Xiamen's CE Marked COVID-19 Nucleic Acid Test Kits. Following the lift of the export ban the COVID-19 Nucleic Acid Test Kits are now able to be exported from China for sale throughout the European Economic Area subject to individual countries accepting import of the test kit. The company has a 46.65% interest in the equity of TBG Xiamen. | 05/05/2020 |
The company issues a Response to ASX Query Letter. | 15/04/2020 |
TBG Xiamen's COVID-19 Virus Diagnostic Kits do not currently have China medical device product registration certification required under the new export requirements as recently announced by the Chinese Government, therefore TBG Xiamen are currently unable to sell and export their COVID-19 Nucleic Acid Diagnostics Kits from China. Without the China medical device product registration certification, TBG Xiamen is also currently unable to sell their COVID19 Nucleic Acid Diagnostics Kits within China. While TBG Xiamen has received interest from several buyers, in light of these new restrictions no COVID-19 Nucleic Acid Diagnostics Kits will be exported or sold while these restrictions remain in place or until TBG Xiamen receives the required certifications for sale and export. | 06/04/2020 |
The securities of TBG Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.3, pending further enquires by ASX. The securities will remain suspended until further notice. | 19/03/2020 |
The securities of TBG Diagnostics Limited (the "Company") will be reinstated to official quotation from the commencement of trading on Wednesday, 3 February 2016, following the Company's compliance with listing rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. Security Code: TDL | 02/02/2016 |
name changed from Progen Pharmaceuticals Limited | 02/02/2016 |
Shareholders in this company should consider crystallising a capital loss in 2024/25 by selling their shares. This process is now much easier and quicker. It can be achieved online by entering transaction details here. While, this usually makes good economic sense we recommend you seek professional advice before buying or selling securities, your accountant is probably the best person. | 10/07/2024 |
delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15 | 30/08/2021 |
we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2022 | 30/08/2021 |
The company has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2022, and the entity's securities are already suspended from quotation. | 23/08/2021 |
The company lodges its Quarterly Activities/Appendix 4C Cash Flow Report. | 03/08/2021 |
The company releases the results of its meeting. | 29/07/2021 |
The company releases a Restatement of its FY2020 Financial Statements. | 29/07/2021 |
The company releases its Annual General Meeting Letter to Shareholders. | 25/06/2021 |
The company's 2020 AGM will be held at 1:00 pm (AEST) 29 July 2021 via a virtual meeting. | 25/06/2021 |
TBG Diagnostics Limited has entered into an agreement for the sale of shares held by the Company in its subsidiary company, TBG Inc. with Dong Yuan Hua Xin (Beijing) Capital Management Limited Company. The Company is selling approximately 5% of TBG Inc to Dong Yuan under this transaction. Following completion of the Company's sale of 5% of TBG Inc to Dong Yuan pursuant to the Agreement, the Company will hold a 41.25% shareholding and Dong Yuan will hold a 38.71% shareholding in TBG Inc. | 07/06/2021 |
The company will hold its AGM on 29 July 2021. The time and other details relating to the meeting will be advised in the notice of meeting to be sent in due course. The period for nomination of directors will close on 10 June 2021. | 20/05/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 03/05/2021 |
The company releases an Appendix 4G. | 31/03/2021 |
The company lodges its Annual Report to shareholders. | 31/03/2021 |
The company lodges its Full Year Statutory Accounts. | 31/03/2021 |
On 12 March 2021, ASIC made a determination restricting TBG Diagnostics Limited from relying on the exceptions in sectin 713 to use transactino-specific disclosure until 11 March 2022. This restriction means that the company will not be able to rely on the reduced disclosure rules under section 713 and instead must issue a full prospectus in order to raise funds from certain investors. The restriction will not affect the operation and business of TDL. | 18/03/2021 |
The company issues a Response to ASX Query Letter. | 03/03/2021 |
The company lodges its Preliminary Final Report. | 26/02/2021 |
The company lodges its Quarterly Activities Report and Appendix 4C. | 01/02/2021 |
The company releases its Securities Trading Policy. | 20/11/2020 |
The company's investee company, TBG Biotechnology XIamen, has received the CE Mark approval for its SARS-CoV-2 Antigen Rapid Test. | 11/11/2020 |
The company lodges its Quarterly Activities Report. | 02/11/2020 |
The company lodges its Appendix 4C - quarterly. | 02/11/2020 |
The company's wholly owned subsisiary, TBG Biotechnology Corp., entered into a distribution agreement with Medigen Biotechnology Corp. on 15 February 2020 to distribute TBG Taiwan's SARS-CoV-2 related diagnostic products, including Rapid Test Kit and Nucleic Acid Test Kit. The Distribution Agreement has expanded Medigen's existing exclusive distribution right granted under the distribution contract previously entered into between TBG Taiwan and Medigen in January 2015 to include the Test Kits. This provides an ability for expansion of the business of manufacturing and distributing the Test Kits through the distribution expertise and network of Medigen. | 21/09/2020 |
The company's wholly owned subsidiary, TBG Biotechnology Corp., has received an Emergency Use Authorisation from the U.S. FDA for its TBG SARS-CoV-2 IgG / IgM Rapid Test Kit. | 02/09/2020 |
The company lodges its Half Yearly Report and Accounts. | 31/08/2020 |
The company lodges its Quarterly Activities Report. | 31/07/2020 |
The company lodges its Appendix 4C - quarterly. | 31/07/2020 |
The company releases the Results of its Meeting. | 31/07/2020 |
TBG Diagnostics Limited's wholly owned subsidiary, TBG Biotechnology Corp., has received an emergency use authorisation from the Taiwan Ministry of Health and Welfare for its ExProbe SARS-CoV-2 Testing Kit. | 29/07/2020 |
The company's 2019 AGM will be held at 12:30 pm (AEST) 31 July 2020 at Boardroom, Level 27 101 Collins Street Melbourne VIC. | 26/06/2020 |
The company releases an Appendix 4G. | 15/06/2020 |
The company lodges its Annual Report to shareholders. | 15/06/2020 |
The company lodges its Full Year Statutory Accounts. | 12/06/2020 |
TBG Biotechnology Corp. has received an Emergency Use Authorisation from the United States Food and Drug Administration for its ExProbe SARS-CoV-2 Testing Kit. | 12/06/2020 |
The company will hold its AGM on 31 July 2020. The time and other details relating to the meeting will be advised in the Notice of Meeting to be sent in due course. The period for nomination of Directors will close on 18 June 2020. | 11/06/2020 |
The company's wholly owned subsidiary, TBG Biotechnology Corp., has received the CE Mark approval for its ExProbe SARS-CoV-2 Testing Kit and SARS-CoV-2 IgG / IgM Rapid Test Kit. | 21/05/2020 |
The company has received notification from TBG Biotechnology Xiamen Inc. that the Chinese Department of Commerce has lifted the bans restricting the exportation of TBG Xiamen's CE Marked COVID-19 Nucleic Acid Test Kits. Following the lift of the export ban the COVID-19 Nucleic Acid Test Kits are now able to be exported from China for sale throughout the European Economic Area subject to individual countries accepting import of the test kit. The company has a 46.65% interest in the equity of TBG Xiamen. | 05/05/2020 |
The company issues a Response to ASX Query Letter. | 15/04/2020 |
TBG Xiamen's COVID-19 Virus Diagnostic Kits do not currently have China medical device product registration certification required under the new export requirements as recently announced by the Chinese Government, therefore TBG Xiamen are currently unable to sell and export their COVID-19 Nucleic Acid Diagnostics Kits from China. Without the China medical device product registration certification, TBG Xiamen is also currently unable to sell their COVID19 Nucleic Acid Diagnostics Kits within China. While TBG Xiamen has received interest from several buyers, in light of these new restrictions no COVID-19 Nucleic Acid Diagnostics Kits will be exported or sold while these restrictions remain in place or until TBG Xiamen receives the required certifications for sale and export. | 06/04/2020 |
The securities of TBG Diagnostics Limited will be suspended from quotation immediately under Listing Rule 17.3, pending further enquires by ASX. The securities will remain suspended until further notice. | 19/03/2020 |
The securities of TBG Diagnostics Limited (the "Company") will be reinstated to official quotation from the commencement of trading on Wednesday, 3 February 2016, following the Company's compliance with listing rule 11.1.3 and Chapters 1 and 2 of the ASX Listing Rules. Security Code: TDL | 02/02/2016 |
name changed from Progen Pharmaceuticals Limited | 02/02/2016 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 11/01/2016 | Stanley Chang | On market | 500,000 | $0.210 | $105,000 |
| 14/05/2014 | Jitto Arulampalam | On market | 40,000 | $1.010 | $40,398 |
| 12/03/2014 | Heng Tang | On market | 10,000 | $0.520 | $5,200 |
| 12/12/2013 | Heng Tang | On market | 10,000 | $0.220 | $2,196 |
| 06/12/2013 | Heng Tang | On market | 33,000 | $0.227 | $7,475 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jitto Arulampalam | Executive Chairman | 12/06/2013 |
| Willy Hsu | COO | 01/02/2019 |
| Emily Lee | Non Exec Director | 07/12/2015 |
| Bing-Cheng Liu | Non Exec Director | 22/03/2021 |
| Stanley Chang | Non Exec Director | 07/12/2015 |
| Justyn Stedwel | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Hsi-Kai Wang | Non Exec Director | 28/05/2018 | 22/03/2021 |
| Eugene Cheng | Non Exec Director | 07/12/2015 | 28/05/2019 |
| Edward Chang | Non Exec Director | 03/02/2016 | 28/05/2018 |
| Christopher Harvey | Independent Director | 16/03/2015 | 07/12/2015 |
| Hongjen Chang | Non Exec Director | 29/11/2013 | 07/12/2015 |
| Heng Tang | Managing Director, CEO | 17/07/2009 | 16/03/2015 |
| Stuart James | Non Exec Chairman | 01/07/2009 | 28/11/2013 |
| Woei-Jia Jiang | Director | 16/06/2011 | 12/07/2013 |
| Paul Dixon | CFO | 03/04/2009 | 12/10/2012 |
| Thomas Burt | Non Exec Director | 17/07/2009 | 30/11/2011 |
| Sue MacLeman | CEO | 06/04/2010 | 26/08/2011 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
